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Abstract 
Many firms actively disclose research findings in scientific peer-reviewed journals. The literature 
highlights several potential benefits of such scientific boundary-spanning activities, including privileged 
access to academic information networks. However, scientific disclosure may lead to unintended 
knowledge spillovers. It remains unclear whether active engagement in science leads to higher returns. 
This paper investigates the impact of scientific activities on the firm’s market value, using accounting 
data for US firms and matched patent and scientific publication data. We find evidence for the positive 
impact of scientific publications on a firm’s market value beyond the effects of R&D, patent stocks and 
patent quality and also document heterogeneity with respect to this impact between different industrial 
sectors. 
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1  Introduction 
Research and Development (R&D) is an important source of competitive advantage for companies. In 
particular, investments in upstream research lead to the creation of new knowledge inside a firm and 
also facilitate the absorption of academic institutions’ and researchers’ latest knowledge (Cohen and 
Levinthal 1989; Rosenberg 1990). Consequently, firms investing in research may produce radical 
inventions which promise greater financial returns. Interestingly, many companies involved in R&D not 
only absorb external academic knowledge but actively contribute to open science by disclosing their 
own findings in scientific peer-reviewed journals (Hicks 1995).  
The literature highlights several mechanisms through which firms who adopt academic disclosure 
practices might benefit. Broadly summarizing, advantages include increased capacity to absorb external 
knowledge, the realization of signaling benefits which facilitate access to valuable research inputs such 
as hiring of PhD graduates, and the promotion of science-based products among professional customers 
(Hicks 1995; Stern 2004; Polidoro and Theeke 2012). However, the dissemination of research findings 
in scientific journals may also lead to unintended knowledge spillovers that facilitate imitation by 
competitors and other specific costs associated with the disclosure process (Arrow 1962; Cockburn et 
al. 1999; Kinney et al. 2004; Stuart and Liu 2014). Although empirical studies document that firms with 
scientific publications lodge higher quality patents (Cockburn and Henderson 1998; Gittelman and 
Kogut 2003; Fabrizio 2009), these studies disregard the potential spillover costs caused by scientific 
disclosure. It remains unclear therefore whether increased R&D productivity by a firm genuinely 
translates into higher financial profitability.  
In this paper, we address this question and investigate the profitability implications of scientific 
disclosure. In order to capture all positive and negative effects, we apply a market value approach 
(Griliches 1981; Jaffe 1986; Hall 1993; Hall et al. 2005). Financial markets react immediately to new 
information and anticipate future commercial implications. Thus, this approach avoids making 
assumptions about time lags between knowledge creation, disclosure effects, and the realization of 
financial returns. We separate - conceptually and empirically - the creation of scientific outcomes from 
the voluntary disclosure of these outcomes in scientific peer-reviewed journals. We also provide initial 
insights regarding the broad mechanisms through which scientific publications may create value. A 
further distinctive contribution is that unlike the majority of studies dealing with science in the corporate 
context which refer to the biotechnology and pharmaceutical industries, the present paper considers all 
high-technology sectors. Since sectors differ according to their appropriability conditions (Levin et al. 
1987; Cohen et al. 2000) which may moderate spillover risks of disclosure, we examine sector 
heterogeneity in greater detail.  
Our empirical analysis uses firm-level information from the US Compustat database, and matched 
scientific publication and patent data for a representative sample of 1,739 stock-market listed firms 
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(9,920 firm-year observations) from all high-technology sectors, covering the period 1996-2006. The 
results of our econometric analysis suggest a positive relationship between the scientific publications of 
firms and their Tobin’s Q. We find evidence that disclosure in high-quality journals, which indicates 
active involvement in science, is especially valuable in terms of higher stock market premium. However, 
we detect a certain degree of heterogeneity across high-technology sectors: whereas scientific 
publications are associated with positive returns in the instruments sectors, and to some extent also in 
pharmaceutical and biotechnology, we find a negative but non-significant tendency in the ICT sectors.  
 
2  Theoretical background 
This paper builds on the already large body of literature examining the relationship between R&D and 
market value, and on recent work investigating the scientific activities of profit-oriented firms. With 
regard to the former, several studies have examined the impact of R&D expenditures, patent stocks and 
patent quality indicators on firm value (see Hall 2000; Czarnitzki et al. 2006, for surveys; Hall et al. 
2005). The majority highlights a positive effect of R&D and patent stocks on the firms’ market value, 
including a premium for high-quality patents. More recent studies have taken into account the strength 
of the appropriability regime, complementary assets and knowledge spillovers as moderating factors on 
this impact (Cockburn and Griliches 1988; MacGahan and Silverman 2006; Belenzon 2012). To date 
however, few studies have considered heterogeneity of R&D activities across firms. One exception to 
this in accounting literature is the study by Deng et al. (1999) which found a positive effect of executing 
scientific research on firm value. However that study did not analyze voluntary contributions of firms 
to the stock of open science. Instead, the authors relied on non-patent literature references in a firm’s 
list of patents as a proxy for scientific research. We build on their work and offer a more complete 
perspective, with a special focus on the impact of the active participation of firms in the scientific 
community, tangibly reflected in scientific publications.  
From a conceptual point of view, there are several reasons why the scientific activities of firms 
may have implications for firm profitability. Firms engaging in (basic) research may develop superior 
capabilities, in that they may be able to combine technologically distant knowledge to create inventions 
which are more valuable than those created by other firms. Such firms are potentially able to absorb 
external knowledge and identify promising trajectories for applied research and experimental 
development, leading to superior inventive outcomes (Rosenberg 1990; Cohen and Levinthal 1989; 
Gittelman and Kogut 2003; Fleming and Sorenson 2004; Fabrizio 2009). While these studies also 
suggest a positive relationship between research investments and firm profitability, the potential costs 
of basic research are not considered. In particular, basic research findings do not necessarily lead to high 
commercial success since translating findings into concrete products can be challenging (see Nelson 
1959; Rosenberg 1990; Cockburn et al. 1999; Pisano 2006).  
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Beyond the creation of scientific knowledge, many firms also voluntarily disclose their research 
results in scientific journals. Such involvement in open science may create value through several 
mechanisms associated with access to upstream knowledge and appropriation (see Penin 2007 for a 
review). With regard to upstream knowledge, disclosing research results may not only increase the 
absorptive capacity (Cockburn and Henderson 1998), but may facilitate knowledge sourcing from 
academic scientists, thanks to reciprocity in knowledge exchange. More specifically, academic scientists 
may be reluctant to interact with scientists from firms unless the latter share valuable research results 
(Hicks 1995; Simeth and Raffo 2013). Moreover, scientific publications can be leveraged as a human 
resource instrument with regard to PhD graduates. Many scientists who consider the private sector as a 
career option value the possibility of continuing publication activities, and may seek out firms engaging 
in this practice (Stern 2004; Sauermann and Roach 2013). Scientific publications are also considered a 
potential appropriability device. Disclosure may encourage the adoption of science-based products such 
as medical drugs or instruments (Azoulay 2002; Polidoro and Theeke 2012). Clinicians, as users of 
medical instruments, influence procurement decisions in university hospitals and are keen to understand 
about the technological characteristics of the products. Manufacturers of such devices might gain greater 
credibility among these clinicians by disclosing related information in scientific peer-reviewed journals. 
Another appropriation-related use of scientific documents is the establishment of prior art through 
disclosure, the aim being to hamper patenting strategies of competitors working on similar inventions 
(De Fraja 1993; Parchomovsky 2000; Della Malva and Hussinger 2012).  
However, the publication process has related costs. The most obvious of these are unintended 
knowledge spillovers that may enable competing firms to learn from the disclosed knowledge (Arrow 
1962). Knowledge spillovers may reduce the cost of imitation for competitors, offer the latter insights 
into future trends and facilitate their exploration of alternative technological trajectories. In addition, the 
publication process itself can lead to opportunity costs since a firm’s researchers have to prepare 
documents which meet the publishing requirements set down by journals, interact with referees and 
codify tacit knowledge (Kinney et al. 2004). Furthermore, firm scientists who publish are more visible 
to competing firms, which may impose the need for retention strategies as their external employment 
options increase (Stuart and Liu 2014; Kim and Marschke 2005). In summary, the positive and negative 
effects of the relationship between corporate science and firm value underline the need for further study 
in this area. 
 
3 Data and Methodology 
3.1  Data sources 
Our analysis was based on a sample of US public companies from high-technology industries, as defined 
by the OECD (OECD 2011), including pharmaceuticals and biotechnology, telecommunication 
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equipment and semiconductors, aircraft, as well as scientific and medical instruments. We also included 
the chemicals sector since it is often recognized as science-oriented. These industries were a natural 
choice as they draw on scientific knowledge as an input factor, while their publication output is varied 
(Cohen et al. 2002; Simeth and Raffo 2013). Firm-level data came from Standard and Poor’s Compustat, 
patent data from the Worldwide Patent Statistical Database (Patstat, version April 2014) provided by 
the European Patent office, while publication data came from Elsevier’s Scopus database. As coverage 
of Scopus changed considerably in 1996, we were obliged not to include earlier periods in our analysis.1 
Moreover, the patent information concerning the United States Patent and Trademark Office (USPTO) 
patents contains the caveat that applications filed before 29th November 2000 but not granted are 
unobservable.2 In order to keep the numbers of patents comparable over time, we therefore only 
considered patent applications where we observed the grant within seven years after the application date. 
This allowed for the inclusion of patent data until 2006. Consequently, the sample covers the time period 
1996-2006, and firms were considered for selection based upon the criterion that they invested in R&D 
in at least one of the years during this period.  
Combining firm-level data with publication and patent information may lead to errors arising from 
name-based matching procedures. To achieve high recall rates of publication and patent numbers, we 
carefully pre-cleaned all firm names by correcting misspellings and removing abbreviations denoting 
corporate structure (e.g. “Inc.”). The publication and patent matching processes differed as scientific 
publications were retrieved manually from the Scopus online database, whereas patent data was matched 
using an offline source. The former is a more time-consuming process than “automatic” offline 
matching, and the latter requires extensive manual cleaning of the algorithm-based matching results. 
Manual retrieval of publication data enabled us to directly inspect hits and immediately exclude other 
institutions with an identical name. The process is explained in further detail in Appendix A.1. For the 
offline matching procedure with patent data from the Patstat database we first pre-tested all names to 
detect problematic cases. Firms with ambiguous names were either excluded directly or marked for 
detailed manual inspection once the actual matching took place. Second, we applied name 
standardization routines both to the names of our sample firms and the applicant field in the Patstat 
database. Third, after testing several matching algorithms, we identified the one which achieved the 
highest recall rate while simultaneously limiting false positive hits (see Raffo and Lhuillery 2009). The 
resulting matches were checked manually with particular focus on firms with atypical input-output ratios 
and those identified in the pre-tests as being uncertain. In order to cross-check the quality of our patent-
                                                     
1
 Scopus extended its journal coverage considerably in 1996, potentially inducing bias to the econometric 
estimations. See http://www.info.sciverse.com/UserFiles/2508.SciVerse.Scopus_Facts_Figures%28LR%29.pdf. 
2
 The policy change was introduced by the American Inventors Protection Act (AIPA) and concerns all patents 
that seek protection in the United States (except patents that enter into the PCT procedure for worldwide protection 
and “opt-out” cases). As of 29th November 2000 all patent applications are disclosed with the search report of the 
patent examiner after 18 months.  
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matching process, we also combined our data with the Compustat-NBER dataset (see Hall et al. 2001), 
performing regressions on the patent numbers based first on our matching and then on Compustat-NBER 
matching. The results were consistent. Since the Compustat-NBER dataset also considers static 
ownership structure (for the year 1989), this exercise suggests that our results were not affected by our 
inability to take into account subsidiaries of the studied companies in the present study. However, it is 
still theoretically possible that we missed a relevant number of publications when not considering 
subsidiaries. To mitigate such concerns, we searched for information on subsidiaries for some of the 
investigated sectors (Biotech SIC 2845 & 2846, Semiconductors SIC 3674, Instruments SIC 3841 & 
3842) and downloaded publications taking into account the names of the subsidiaries using the SEC 
security filings (report “10-K”). The corresponding regressions suggested that no bias arose from the 
non-consideration of subsidiaries in our analysis (see Appendix A.2). 
To reduce biases originating from Merger & Acquisition (M&A) activities, measurement errors 
and “atypical” firms (e.g. specialized R&D firms with a majority of shares owned by business groups), 
several filters were applied to the sample. First, to limit potential biases from M&A events, firms with 
large changes in book value were identified based on the criteria of an increase of more than 300% or 
decrease of more than 75% over a period of two consecutive years (Griliches 1981; Hall and Oriani 
2006; Aldieri and Cincera 2009). We only dropped the firm-year observation when a large change 
occurred. In such cases, we treated the firm in subsequent years as a new firm (Griliches and Mairesse 
1984). Excluding firms involved in M&A activities entirely could have led to selection bias since M&A 
activities are presumably often based on successful R&D operations. To address measurement errors 
and inaccurate initial knowledge stock computations, we also dropped observations with extremely high 
(the top 1%) knowledge-to-asset ratios.3 Finally, we excluded firms with fewer than 10 employees, 
imposed a minimum sales amount of 500,000 USD, and removed firms with an R&D/Sales ratio higher 
than one. A firm with no sales generates a high degree of uncertainty among investors in terms of its 
survival prospects. Such firms are therefore at a different structural stage than those already generating 
a cash flow, the result likely being heterogeneous treatment on the stock market. In our study, since the 
R&D/Sales ratio filter affected a notable number of observations, we removed it as a robustness test (see 
Section 4.4). The final sample size contained 9,920 firm-year observations, composed as follows:  
 
       -- Insert Table 1 here -- 
 
Finally, all financial amounts were adjusted for inflation using the Gross Domestic Product (GDP) 
deflator.    
                                                     
3
 The three measures concerned are R&D/A, PAT/R&D, PUB/R&D which are explained in detail in section 3.2. 
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3.2 Variables 
To construct our dependent variable, we applied the methodology followed by previous related research 
and used the Tobin’s Q which represents the ratio of a firm’s market value to its book value. Market 
value is the addition of the market value of the equity and the market value of the debts. The former is 
calculated by the number of outstanding shares multiplied by the stock price at the end of the fiscal year, 
whereas the latter is approximated using the book value of liabilities (Blundell et al. 1999; Hall and 
Oriani 2006, Ceccagnoli 2009). The firm’s book value is represented by its assets at the end of the fiscal 
year. With respect to the independent variables, one core measure is the firm’s R&D investments which 
reflect overall commitment to knowledge production. The investments in R&D take place in a particular 
period, but the returns on these investments may last much longer. Therefore, we introduced a stock 
measure of R&D. Since knowledge becomes obsolete because of ongoing technological development, 
we applied the frequently used perpetual inventory method with an annual 15% depreciation () rate 
(Griliches and Mairesse 1984; Hall et al. 2005). In the absence of a strong theoretical justification for 
assuming different rates for the other knowledge-related measures, we not only computed the R&D 
stock but also the publication and patent stock indicators with the 15% rate as follows: 
& 	
 = & + 1 − )& 	
          (1) 
Although the computation of the R&D stocks is technically straightforward, assumptions have to 
be made regarding the initial stock (& 	
) which remains partly unobserved. In our study, 
we applied a standardized growth rate (g) for R&D and the other knowledge stock measures of 8%, 
given that our sample contained only high-technology firms (Hall and Oriani 2006; Hall et al. 2007).4 
All knowledge-related measures discussed below are accordingly constructed as stocks. We constructed 
three measures directly related to the firms’ scientific operations. First, we use a patent-based indicator 
to measure outcomes from basic research, and thus indirectly also measure a firm’s potential to create 
scientific publications (SCIPAT). It is assumed that the existence of a scientific document in the 
backward references of a patent indicates a science-based patent (Narin et al. 1997; Deng et al. 1999). 
We identified scientific documents in the Non-Patent-Literature (NPL) section of patents’ backward 
references using specific keywords and character combinations collected via extensive screening of the 
raw NPL information. Since this measure captured research outcomes but did not depend on the 
observation of scientific contributions to academic journals, the use of SCIPAT, in combination with the 
publication-based indicators, enabled us to differentiate between research outcomes and disclosure 
                                                     
4
 This applies specifically to firms that do not have a long pre-sample record in Compustat. The stocks can be (at 
least partly) computed with observed values for firms with IPO’s before 1996. In formal terms, the initial R&D 
stock is approximated as follows: & 	
 = & / + ) 
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effects.5 Although this measure of basic research relies on patented outcomes, we nonetheless 
considered it to be a reasonable measure, given that our sample comprised only firms from high-tech 
sectors with a high propensity to patent.  
Second, we captured the number of voluntary scientific contributions by computing a stock 
measure based on the number of scientific papers published by each firm (PUB). Given our use of 
SCIPAT to measure basic research outcomes, the publication stock should not only reflect research 
productivity but also effects deriving from the disclosure of results. Moreover, to consider the 
heterogeneity of scientific contributions, we introduced a second measure reflecting their academic 
quality (TOPPUB). If firms are able to publish in prestigious journals, it is likely that the degree of 
involvement in the scientific community will be higher. Publishing in highly ranked journals is also less 
likely to reflect appropriation motives since the publication process is riskier with higher likelihoods of 
rejections and delays imposed by referees’ requests for further experiments before accepting the 
submitted article. In order to overcome potentially imperfect corrections for field effects and inaccurate 
weightings of articles by impact factors, we decided to rely on a simpler dichotomous distinction by 
identifying the top 10% of journals based on the impact factor distribution within the five meta-
disciplines: Life Sciences, Physical Sciences and Engineering, Social Sciences, Health Sciences and 
General/Interdisciplinary. The computed stock variable therefore only considered scientific documents 
published in these top journals (see Appendix A.3).   
In line with previous literature, we included two measures reflecting the amount of inventive 
outputs and their quality. The absolute amount of inventive outcomes is represented by patent stocks 
(PAT) and the quality of the inventive outcomes (FWDCIT) is measured using forward citation counts 
(Hall et al. 2005). To deal with the truncation problem of citation counts, we considered only those 
citations that occurred within a five-year window after the priority date of our focal patents (Lanjouw 
and Schankerman 2004; Marco 2007). Finally, we included sector and year dummy variables to take 
into account heterogeneous market valuations across industries and time (Cockburn and Griliches 1988; 
Hall et al. 2005).  
  
3.3 Model and estimation techniques  
In this paper, we analyze the relative market value of firms (Tobin’s Q) as a function of their knowledge 
stocks. We rely on the well-established market value function (Griliches 1981, Hall et al. 2005) which 
                                                     
5
 Taking into account the possibility that SCIPAT might not exhaustively capture the basic research outcomes, we 
also included a stock of “original” patents based on the patent originality measure proposed by Trajtenberg et al. 
(1997). The results of this specification are reported in the appendix A.4 and are consistent with those of the main 
model.  
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regards tangible (Ait) and intangible assets (Kit) as additives (“hedonic model”). The function can be 
formalized as follows: 
, ) =   , )                             (2) 
In this equation, qit represents the valuation coefficient of a firm’s assets, and the parameter γ allows 
for the eventuality that knowledge assets are valued differently from physical assets. The valuation 
coefficient qit may vary across time and industries and also contains a firm-specific component. The 
factor σ represents scale effects and is assumed to equal 1, which is also confirmed in our data (Hall et 
al. 2005). Applying logarithms on both sides and moving tangible assets to the left-hand side of the 
equation yields the following expression:           
     
Log "#$%&$%'  = log ) = log  + log "1 +   
*$%
&$%
' + +            (3) 
Following our theoretical discussion, we separate the knowledge intangibles of firms into R&D, 
patent stocks, and publication stocks. Since patents and scientific publications can be regarded as direct 
outcomes of R&D inputs, we introduce these additional measures as ratios denominated by R&D 
expenditures (Hall et al. 2005; Hall and Oriani 2006; Hall et al. 2007), formalized in Equation (4):  
 
Log "#$%&$%'  = log ) = log  + log "1 +  
,&-$%
&$%
 +  . /&0$%,&-$% +   1
/23$%
,&-$%
 
 ' +  +            (4) 
In our empirical setting, R&D, PAT and PUB represent the respective stock measures computed 
using the perpetual inventory method with an assumed depreciation rate of 15%. In the full specification, 
we distinguish between the impacts of (basic) research and disclosure effects using further measures 
that are introduced as ratios and which are orthogonal to the main variables. These further variables 
reflect science-based inventions (SCIPAT/PAT), the quality of the inventive output (FWDCIT/PAT), and 
the academic impact of scientific output (TOPPUB/PUB). Consequently, the extended model of 
Equation (4) can be written as: 
 
45 "#$%&$%' = log ) = log  + log  "1 +  
,&-$%
&$%
   +  . /&0$%,&-$% +   1
/23$%
,&-$%
+ 6 789/&0$%/&0$%    +     
+ : ;<-890$%/&0$%  +  =
0>//23$%
/23$%
' +  +                    (5)    
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Equations (4) and (5) can be directly estimated using Non-Linear Least Squares (NLLS). Instead, OLS 
regression models can be applied only by using the approximation log (1+x) ~ x. Nevertheless, higher 
values of x lead to imprecisions in the estimated outcome. An important concern is the potential presence 
of unobserved firm heterogeneity. However, independent variables are potentially predetermined since 
past firm valuations may influence current investment decisions related to R&D strategies. This 
eventuality violates the strict exogeneity assumption for the “within” estimator. Moreover, unlike the 
rather volatile Tobin’s Q indicator, the innovation-related variables change slowly over time and are 
thus highly correlated with the firm-specific effect. Consequently, a “within” fixed-effects estimator 
may rather exacerbate estimation problems than allow valid estimates to be obtained (see also Hall et 
al. 2005). A potential solution, suggested by Blundell et al. (1999), is the introduction of a pre-stock 
average of the firm’s market value as an additional regressor. We tested this approach, but it led to a 
substantially decreased sample since many firms do not have a sufficiently long stock market history. 
Consequently, like most of the related empirical literature, we decided to focus on NLLS regression 
models.  
 
3.4 Descriptive statistics 
In Table 2 we provide an overview of the mean and median values as well as the standard deviation of 
the regression variables and selected additional measures that provide information about firm 
characteristics.  
  -- Insert Table 2 here -- 
Since all firms were stock market-listed, the sample consisted predominantly of medium- and 
large-sized firms. However, median values suggest considerable heterogeneity among our sample of 
firms. The median values for annual R&D expenditures were 8.36 million USD, 79.41 million USD for 
sales and 340 for the number of employees, whereas the mean values were much higher, indicating the 
presence of both large but also medium-sized and small firms. The average Tobin’s Q ratio was quite 
high at 2.65. In 12.3% of the firm-year observations, the market valuation was below the book value. 
With regard to trends in publication and patent outputs, the share of both publishing and patenting firms 
increased over time. Time trends are shown in Figures 1 and 2.  
 -- Insert Figure 1 & 2 here -- 
The average number of publications and patents by a firm both increased over time. At the 
beginning of the sample period the number of patents continuously increased while the number of 
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publications remained stagnant, before starting to increase in 2002. Interestingly, the average level of 
publication and patent activity did not differ greatly, which is remarkable given that firms are, by 
definition, not concerned with contributions to the stock of scientific knowledge per se. With regard to 
the share of firms with at least one publication or patent in a given year, we obtained the following 
picture as reported in Figure 2: the share of publishing firms increases from 37% in 1996 to 53% in 
2006, whereas the share of patenting firms increased from 46% in 1996 to 60% in 2006. Output types 
appeared to be complementary since the majority of publishing firms in a given year also filed a patent 
application. Over time, there was an increase in the strategy to patent and publish simultaneously. In 
2006 however, 14% of all firms only published, 17% only created patents, and 26% of firms neither 
created patents nor published.  
4 Econometric results and discussion 
4.1 Full sample estimations 
The core specifications of the econometric analysis are shown in Table 3. Considering the elements 
highlighted in the previous section, we estimated Tobin’s Q with both non-linear and linear regression 
models, but ultimately focused on the interpretation of the former since non-linear models enable the 
theoretical model to be directly represented. In order to evaluate the quantitative impact of our variables 
in the NLLS regressions, we also computed semi-elasticities (at the mean values of the variables) which 
are reported in complementary columns for the baseline (2) and full (6) NLLS regression models.6  
        -- Insert Table 3 here -- 
 
In columns (1)-(2), we estimated baseline specifications using NLLS and OLS estimators. All three 
knowledge measures representing R&D (R&D/A), patent (PAT/R&D) and publication (PUB/R&D) 
stocks had a positive and significant effect on Tobin’s Q, the latter two having similar magnitudes. One 
additional patent per million dollars of R&D was associated with an increase of 9% in Tobin’s Q, and 
10% for an additional publication per million dollars of R&D. This result provided a first indication that 
scientific activities have an important impact on the market value of firms. In order to obtain a more 
detailed picture, we introduced the additional measures described in Section 3.3. In columns (3)-(5), we 
first separately added the three variables FWDCIT/PAT, SCIPAT/PAT and TOPPUB/PUB to the 
baseline model. All three measures exhibited a value premium for Tobin’s Q. The main variables 
remained statistically significant when the supplementary patent-based variables were included. 
                                                     
6
 Semi-elasticities can be obtained by calculating the derivative of the estimated market value equation with 
regard to the variable of interest. See Hall et al. (2005) for further details.  
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However, when adding the measure capturing the share of publications in prestigious journals 
(TOPPUB/PUB) in column (5), the magnitude of the publication stock PUB/R&D decreased, and the 
variable only remaining significant at the 10% level. In columns (6)-(7), we report the regression results 
with the full variable set. In the NLLS specification (6), it can be seen that R&D stocks, patent stocks 
and patent citation stocks (FWDCIT/PAT) had a positive impact, which is in line with findings from 
previous studies (e.g. Hall et al. 2005). While publication stocks (PUB/R&D) were only significant at 
the 10% level, we detected a strong positive and highly significant effect of publications in top journals. 
The increase of the variable by one unit – which is equivalent to a change from none of a firm’s 
publications being in top journals to all of the firm’s publications being in top journals -  increased 
Tobin’s Q by approximately 12%.7 Interestingly, the impact of science-based patents (SCIPAT/PAT) 
became substantially weaker in comparison to column (4), with the positive effect of a one unit change 
decreasing from 11% to 4%, and the variable becoming statistically insignificant once the share of 
publications in top journals was taken into account.   
Based on these regression results, the question arises as to whether the positive effects of scientific 
activities which we found reflect (i) the successful creation of science-based knowledge outcomes or 
benefits that derive from the disclosure of these outcomes, (ii) signaling benefits to academic audiences 
or the use of publications as a device to support appropriation. We would like to stress that we cannot 
provide conclusive evidence concerning these mechanisms with our measures but can only offer some 
indications which must be treated with caution. In the full model presented in column (6), positive effects 
for scientific publication stocks and especially top journal publications were observed despite the 
presence of science-based patents. While being highly significant and exhibiting a notable magnitude in 
column (4), the measure of science-based patents was no longer significant in the full specification. This 
indicates that the use and absorption of basic research has a positive impact on a firm’s market value. 
However, active involvement in science which is especially represented by publications in top journals, 
generates a considerable market value premium beyond the successful absorption of scientific 
knowledge. The relevance of publication quality also has implications with regard to point (ii) above 
and the underlying value-creating mechanisms of scientific disclosure. Firms that disclose knowledge 
for defensive purposes have an interest in keeping control over the timing of disclosure. As a 
consequence, there are incentives for firms to target lower impact journals as, presumably, the likelihood 
of acceptance in high-impact journals is lower and the time taken to publish longer. Therefore, if this 
mechanism is value-enhancing, we would expect a stronger effect of the main publication stock 
PUB/R&D in the full model. However, the particularly strong effect of publications in high-impact 
journals points more to value deriving from facilitated interactions with academic partners. In other 
                                                     
7
 Caution must be exercised when comparing the magnitudes between PUB/R&D and TOPPUB/PUB due to the 
different units of the variables. Therefore we also calculated the impact of a change by one standard deviation. 
The result of this exercise also suggested that publications in prestigious journals are associated with a particularly 
strong increase in Tobin’s Q (3.7% vs. 1.6%).  
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words, firms actively participating in the scientific community seem to have easier access to valuable 
knowledge and to highly qualified graduates, which results in a higher Tobin’s Q.  
 
4.2 Sector analysis 
Since the association between scientific activities and firm value may differ across industries, especially 
in the light of the relative risks of knowledge spillovers, we analyzed the individual sectors in greater 
detail. In Table 4, we report the results of subsample regressions with the meta-sectors Biotechnology 
and Pharmaceuticals (hereafter BIO-PHARM), Information & Communication technologies (ICT), 
Scientific and Medical instruments (INST), and Chemicals (CHEM).  
-- Insert Table 4 here –  
Starting with the baseline specification, it can be seen that the effect of scientific publication stocks 
differs across the meta-sectors. Although we detected a positive but non-significant sign in BIO-
PHARM and CHEM, a negative and non-significant effect was found in ICT, while a positive and 
significant effect was observed for the INST sectors. Estimating the regression model with the full set 
of variables revealed interesting patterns. In BIO-PHARM, the publication quality indicator was 
significant and of quite a strong magnitude, whereas the variables reflecting the main publication stock 
and science-based patents did not have such an impact. This result suggests that as long as a firm is not 
seriously committing to Open Science, scientific activities will not be sufficient to generate a value 
premium. We observed a similar result for the INST subsample, where the TOPPUB/PUB measure had 
a strong positive effect too. However, the main publication variable PUB/R&D also showed a rather 
strong magnitude in comparison to the other subsamples, and remained significant. This finding suggests 
that in addition to upstream signaling, publications may create value through mechanisms other than 
establishing knowledge flows with the scientific community. One plausible interpretation for this 
finding lies in marketing effects, since firms in instrument sectors sell to scientifically-trained 
professional customers. In order to establish credibility among this audience with regard to the latest 
science-based products, publishing in high-impact journals is presumably less crucial. In the ICT 
domain, we saw a different picture. Publication stocks were negative and the share of top impact journal 
publications also had a negative sign. Interestingly, in addition to the positive effects of patent stocks 
and patent quality, the share of science-based patents was positive and significant. In other words, 
absorbing scientific knowledge and achieving science-based inventions may create value, whereas 
active dissemination of results and participation in the scientific community do not. For the CHEM 
sector, we only observed a positive effect of R&D on the market value. However, there was no premium 
for patent and publication stocks or for science-based patents.  
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 These obtained differences across sectors indicate that appropriability conditions have a notable 
influence on the returns of scientific disclosure strategies. In sectors with strong legal appropriation, like 
the medical instrument and biopharmaceutical industries, we observed positive net returns from 
scientific publications, whereas in the ICT domain, which can be characterized as having a weaker 
appropriability regime due to its complex and cumulative nature, no premium was observed (see Levin 
et al. 1987; Cohen et al. 2000; Hall and Ziedonis 2001). This finding indicates that in the ICT sectors, 
scientific disclosure leads to knowledge spillovers which outweigh any benefits. The result for the 
Chemicals sector, where appropriability conditions are stronger than those in the ICT sector, can be 
explained by the fact that in the former, academic knowledge is only of moderate importance as an input. 
Therefore, the potential benefits of scientific disclosure in terms of signaling might be limited in the first 
place.  
 
4.3 Robustness tests 
Beyond considering subsidiary publications for a subsample of firms, as reported in Appendix A.2, we 
performed further robustness checks, the most important of which are displayed in Appendix A.4. These 
robustness tests did not change our main models’ results. Consequently, we will only describe them very 
briefly. We list several tests and for ease of reading we shall assign them numbers that correspond to 
the respective columns in Appendix A.4. (1) We ran fixed-effect regression models. As discussed in 
Section 3.3, such models must be interpreted with caution in our context. However, the results suggested 
that scientific activities do indeed lead to higher firm values. (2) We removed the filter which initially 
excluded firms whose R&D/Sales ratio was larger than one since this filter was perhaps overly 
restrictive. However, our results after removing this filter did not change. (3) In order to control for 
unobserved selection mechanisms for publication in terms of local spillovers and competition, we 
included state dummies. (4)-(5) Since scientific backward references may not exhaustively capture basic 
research outcomes in firms, we included the patent originality variable as suggested by Trajtenberg et 
al. (1997). This variable behaves very similarly to science-based patents, and supports the interpretation 
that the results for publication stocks do not only reflect research productivity effects but also benefits 
deriving from the active involvement of firms in science. (6)-(8) We introduced additional control 
variables, namely the amount of sales and the growth of sales, sector-level patent and publication 
propensities, and the share of firm’s profit on the industry profit. These controls should capture the effect 
of unobserved intangibles potentially correlated with our knowledge intangibles, of the abilities of firms 
to appropriate returns from R&D, and in the case of the sector-level variables, of incentives to engage 
in publication. Our results did not change when these additional controls were included. (9) We used 
the patent counts from the Compustat-NBER matching (Hall et al. 2001; Cockburn et al. 2009) to verify 
the quality of our own matching. The regression outputs were very similar. (10)-(11) We modelled the 
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market value function in a different way by including the publication stock to patent stock ratio (i.e. 
instead of publication stock to R&D stock ratio) for the subsample of patenting firms. Such a 
specification might be an adequate measure of openness if publications and patents reflect the same 
knowledge. The variable PUB/PAT was found to be positive and significant, supporting the 
interpretation of the core models that publication provides additional value beyond patented knowledge. 
(12) We included an additional measure of the share of publications co-authored with academic 
institutions. This variable had a positive but not significant effect when added to the model with the full 
set of variables. 
 
5 Conclusion 
This study examines the impact of scientific activities of firms on their stock market valuation using a 
dataset of firm-level information for US high technology companies, combined with scientific 
publication and patent data. Although scholars have recently started to conceptually and empirically 
address the determinants of scientific activities by firms, in particular disclosure, there is very little data 
for firm performance effects. Thanks to its design, our analysis provides an empirical contribution not 
only to the growing literature on boundary-spanning activities of firms, but also to more mainstream 
studies assessing the performance implications of R&D in firms.  
Our analysis documents the positive impact of science-related indicators on a firm’s market 
valuation beyond the effects of R&D and inventive outcome indicators. Our measures enabled us to 
differentiate between the profitability implications of performing research and a more active 
involvement in open science. While we cannot entirely rule out the possibility that we also capture 
research productivity effects, our findings suggest that active involvement in science, as reflected by 
disclosure in scientific journals, results in higher stock-market values. Furthermore, our results indicate 
in particular that the positive effects of such disclosure stem from scientific signaling to upstream 
stakeholders, which results in superior knowledge flows from these persons and institutions. In other 
words, publishing allows firms to become members of the scientific community and to establish formal 
and informal interactions, which in turn provide the former with access to state-of-the-art developments 
and research techniques. On the other hand, we found little evidence for a value-enhancing use of 
publications for appropriation purposes. Overall, our study provides support for the increasingly strong 
view among scholars that minimizing knowledge outflows may not be an optimal choice for firms and 
that they should instead strategically disclose knowledge.  
Some heterogeneity concerning the impact of scientific activities was found. A negative but non-
significant sign was found for ICT sectors. Instead, a strong positive relationship was observed in the 
instruments sectors. Therefore, appropriability conditions would seem to matter, which implies that 
R&D managers need to carefully consider the benefits and potential costs caused by related spillovers. 
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To obtain a better understanding of the mechanisms involved, future work could focus on contextual 
conditions that potentially moderate the relationship between scientific activities and the firm’s market 
value. In conclusion, the strengths and weaknesses of the market value approach and corresponding 
empirical limitations should be kept in mind when interpreting results. Financial markets can be very 
volatile, and do not behave completely rationally. Thus, future research could complement our present 
study by using direct financial performance measures. This however, would entail dealing explicitly 
with the time lags between knowledge creation and commercial returns. 
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TABLES AND FIGURES 
Table 1: Observations according to included sectors 
 
 
 
Table 2: Summary statistics 
 
Meta-Sector SIC included
Firm-year 
observations
Biotechnology & Pharmaceuticals 2834, 2835, 2836 1 602
Chemicals 2800, 2810, 2820, 2821, 2833 389
Information and Communication Technologies 
(ICT)
3570, 3571, 3572, 3575, 3576, 
3577, 3578, 3579, 3661, 3663, 
3669, 3670, 3672, 3674, 3677, 
3678, 3679, 4812, 4813, 4822 4 373
Aircraft & Aerospace 3721, 3724, 3728 166
Navigation, Scientific, Medical, and Optical 
instruments
3812, 3822, 3823, 3824, 3825, 
3826, 3827, 3829, 3841, 3842, 
3843, 3844, 3845, 3851, 3861 3 390
Sum 9 920
Variable N Mean Std. Dev. Median Min Max
TOBIN'S Q 9920 2.65 2.39 1.89 0.25 23.02
A (BOOK VALUE) 9920 1548.56 7172.64 94.33 0.55 273007.30
R&D (FLOW) 9920 104.29 468.25 8.36 0.00 12942.19
R&D (STOCK) 9920 491.47 2082.16 39.96 0.00 41408.40
R&D / A 9920 0.61 0.71 0.39 0.00 7.42
PAT (STOCK) 9920 114.33 559.85 5.57 0.00 9969.30
PAT / R&D 9920 0.31 0.46 0.15 0.00 3.68
SCIPAT / PAT 9920 0.27 0.31 0.17 0.00 1.00
FWDCIT / PAT 9920 5.59 7.50 4.38 0.00 198.65
PUB (STOCK) 9920 69.54 347.81 1.77 0.00 6440.20
PUB / R&D 9920 0.15 0.29 0.04 0.00 2.85
TOPPUB / PUB 9920 0.20 0.29 0.00 0.00 1.00
SALES 9920 1229.41 5248.79 79.41 0.50 88784.06
EMPLOYEES 9738 4076.93 14324.04 340.00 10.00 238000.00
Monetary amounts in Mio USD (2005, GDP deflated)
-21- 
 
Table 3: Regression outputs 
  
 
 
(1) (3) (4) (5) (7)
LOG TOBIN'S Q OLS NLLS NLLS NLLS OLS
Coeff (SE) Coeff (SE) Semi-elast. Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Semi-elast. Coeff (SE)
R&D/A 0.048*** 0.055*** 0.051 0.055*** 0.052*** 0.051*** 0.050*** 0.045 0.042***
(0.011) (0.014) (0.015) (0.014) (0.014) (0.015) (0.011)
PAT/R&D 0.083*** 0.097*** 0.090 0.071*** 0.083*** 0.097*** 0.072*** 0.064 0.066***
(0.021) (0.025) (0.026) (0.025) (0.025) (0.026) (0.021)
PUB/R&D 0.095*** 0.110*** 0.102 0.108*** 0.091** 0.066* 0.065* 0.057 0.056*
(0.032) (0.039) (0.039) (0.039) (0.038) (0.039) (0.032)
FWDCIT/PAT 0.007*** 0.006*** 0.005 0.004**
(0.002) (0.002) (0.002)
SCIPAT/PAT 0.124*** 0.046 0.041 0.052
(0.035) (0.037) (0.032)
TOPPUB/PUB 0.168*** 0.142*** 0.126 0.125***
(0.040) (0.041) (0.034)
Firm-Year observations 9,920 9,920 9,920 9,920 9,920
Firm-IDs (cluster) 1.739 1.739 1.739 1.739 1.739
R2 0.129 0.136 0.134 0.136 0.141
Standard errors (clustered by firm) reported in parentheses; *** p<0.01, ** p<0.05, * p<0.1
NLLS
(6)
9,920
1.739
0.141
9,920
1.739
0.130
NLLS
(2)
All regression models contain year and SIC-4 digit industry dummies. The semi-elasticities reported in the table are computed at the mean values of the variables. 
The semi-elasticities of the added variables in columns (3)-(5) are as follows: FWDCIT/PAT  0.007, SCIPAT/PAT  0.113, and TOPPUB/PUB  0.153.
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Table 4: Heterogeneity by sectors 
   
 
 
(1) (2) (3) (4) (5) (6) (7) (8)
LOG TOBIN'S Q NLLS NLLS NLLS NLLS NLLS NLLS NLLS NLLS
Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE)
R&D/A 0.126*** 0.108*** 0.022 0.022 0.086*** 0.075** 0.395* 0.389*
(0.040) (0.041) (0.017) (0.018) (0.029) (0.030) (0.208) (0.206)
PAT/R&D -0.040 -0.028 0.142*** 0.110** 0.103*** 0.079** 0.067 -0.010
(0.067) (0.075) (0.049) (0.048) (0.036) (0.038) (0.115) (0.094)
PUB/R&D 0.133 0.045 -0.009 -0.014 0.218*** 0.149** 0.115 0.058
(0.088) (0.086) (0.049) (0.050) (0.075) (0.075) (0.169) (0.140)
FWDCIT/PAT 0.006 0.003 0.009* 0.022
(0.007) (0.002) (0.005) (0.020)
SCIPAT/PAT -0.037 0.129** 0.021 -0.098
(0.074) (0.058) (0.070) (0.141)
TOPPUB/PUB 0.225** -0.015 0.243*** 0.026
(0.090) (0.054) (0.077) (0.137)
Firm-Year observations 1,602 1,602 4,373 4,373 3,390 3,390 389 389
Firm-IDs (cluster) 331 331 762 762 565 565 57 57
R2 0.071 0.088 0.120 0.127 0.129 0.156 0.136 0.150
Standard errors (clustered by firm) reported in parentheses; *** p<0.01, ** p<0.05, * p<0.1
All regression models contain year and SIC-4 digit industry dummies.
BIO-PHARM ICT INST CHEM
Regression models represent baseline and full model specification for meta-sectors biotechnology and pharmaceuticals (BIO-PHARM) in columns (1) 
and (2), for information and communication technologies (ICT) in (3) and (4), for instruments (INST) in (5) and (6), and for Chemicals (CHEM) in (7) 
and (8). See Table 1 for information on SIC codes included in the meta-sectors. The regression results for the Aircraft sector are omitted in this table 
due to the very low number of observations. The semi-elasticities of the publication-based measures are as follows: PUB/R&D : 0.039 in column (2), -
0.014 in (4), 0.125 in (6), 0.058 in (8). TOPPUB/PUB : 0.195 in column (2), -0.014 in (4), 0.204 in (6), and 0.022 in (8).
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Figure 1a: Average publication & patent outputs 
 
 
 
Figure 1b: Share publishing and patenting firms 
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APPENDIX 
Appendix A1: Matching firm-level data with publication data 
In the absence of any direct linking identifiers, the firm-level data from COMPUSTAT and data from 
SCOPUS have to be combined manually using the firm name (and potential abbreviations) and the 
affiliation field in the publication database. The firm names – as listed in the COMPUSTAT database – 
contain legal identifiers and other elements which may lead to too few matches (“false negatives”). 
Therefore, as a general rule, we reduced the firm names to the most distinctive name components, 
removing frequent name elements and legal identifiers in order to achieve high recall rates. Frequent 
examples included the words “Pharmaceuticals”, “Technologies”, or “International” which typically 
have little identifying power and lead to false negatives when the publication authors do not mention 
the full official firm name. Moreover, although the Scopus engine is not sensitive to name capitalisation 
and language-specific characters, we harmonized firm names correspondingly since this is a useful step 
for post-download processing. It has to be considered that reducing the firm names to a minimum may 
have increased the number of false positive search results. A common source of false positives are, for 
example, university units or independent firms with a common name component. Thanks to the manual 
downloading process, all search results were inspected directly and in the case of ambiguity, a 
complementary web search was used to select only eligible publications. Finally, we performed post-
download verification checks by transforming the affiliation information of the different authors of a 
particular publication into a “long” format, harmonizing the affiliation field with regard to name 
capitalizations and language-specific characters, and applying queries to detect whether the exact field 
that created the link between the firm and publication record simultaneously contained an element 
pointing to an academic institution. In these rare cases, the publication records were manually checked. 
Example: ADHEREX TECHNOLOGIES INC  
This name contains with “Technologies” and “INC” two name components that potentially lead to too 
few search results. The identifier INC was therefore directly removed. Whereas the search using 
“ADHEREX TECHNOLOGIES” led to 21 publications in the period between 1996 and 2010, using 
only “ADHEREX” returned one additional publication. After manual inspection of the search results, 
we concluded that all 22 publications were eligible and we subsequently downloaded the corresponding 
information. Query: AFFILORG (“ADHEREX”) AND PUBYEAR > 1995 AND PUBYEAR < 2007 
 
-25- 
 
Appendix A2: Subsidiary publications 
(1a) (1b) (2a) (2b) (3a) (3b) (4a) (4b)
NLLS NLLS NLLS NLLS NLLS NLLS NLLS NLLS
LOG TOBIN'S Q SUB NO SUB SUB NO SUB SUB NO SUB SUB NO SUB
Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE)
R&D/A 0.065* 0.065* 0.080* 0.082* 0.342*** 0.340*** 0.117*** 0.116***
(0.033) (0.033) (0.044) (0.043) (0.088) (0.087) (0.029) (0.029)
PAT/R&D 0.057 0.056 -0.049 -0.051 0.140** 0.139** 0.052 0.051
(0.071) (0.071) (0.093) (0.094) (0.061) (0.061) (0.041) (0.041)
PUB/R&D 0.128 0.136 -0.025 -0.002 0.064 -0.020 0.104* 0.106
(0.092) (0.097) (0.076) (0.104) (0.132) (0.083) (0.062) (0.066)
Firm-Year observations 1,126 1,126 706 706 798 798 2,630 2,630
Firm-IDs (cluster) 186 186 160 160 145 145 491 491
R2 0.123 0.124 0.056 0.055 0.144 0.143 0.069 0.069
Standard errors (clustered by firm) reported in parentheses; *** p<0.01, ** p<0.05, * p<0.1
All models contain year dummies.
Column (1a) and (1b): SIC 3674 (Semiconductors); (2a) and (2b): SIC 2835 & 2836 (In vitro & in ivo diagnostic substance; 
Biological products); (3a) and (3b): SIC 3841 & 3842 (Surgical & Medical Instruments, Orthopedic and surgical appliances); (4a) 
and (4b): All sectors combined from columns (1)-(3).
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Appendix A3: Definition of top-impact journals  
 
General information 
The distinction as to whether a firm publication was of a high quality was made using journal-impact factor 
information. The data source for journal impact factors was the SCIMAGO classification, which contains 
the SCImago Journal Rank (SJR) indicator based on the records in the Elsevier’s SCOPUS database. The 
SCIMAGO ranking is propagated by Elsevier as an official indicator for SCOPUS. Since the journal 
rankings are dynamic but change in realty slowly over time, we chose the reference year 2000 which is the 
centre year in our sample period.  
URL: http://www.scimagojr.com and http://www.journalmetrics.com 
 
Construction of indicator 
In order to normalize the indicator for field effects potentially not entirely considered in the SJR indicator, 
we created Journal Impact factor rankings specifically for the meta-fields Life Sciences, Physical Sciences, 
Health Sciences, General journals, Social Sciences. We created our top-impact journal indicator based on 
the distribution of the SJR indicator within the five meta-disciplines, and classified the top 10% of all 
journal sources as top-impact journals. The meta-fields contain the following number of journals: 
 * LIFE SCIENCES:   4,646 sources  
 * PHYSICAL SCIENCES:  8,916 sources 
 * HEALTH SCIENCES:  8,483 sources 
 * GENERAL JOURNALS: 95 sources 
 * SOCIAL SCIENCES:   6,687 sources 
 
Examples of journal classification in the Innovation Research field 
To illustrate the outcome of the classification for journals known in the Management field, some examples 
are presented below: 
Classified as Top Impact Journals: Management Science, Journal of Industrial Economics, Journal of 
Economics and Management Strategy, RAND Journal of Economics; Journal of Economic Behaviour and 
Organization, Research Policy 
Not classified as Top Impact Journals: Industrial and Corporate Change, Journal of Technology Transfer, 
Technovation, Industry and Innovation, Small Business Economics 
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Appendix A4: Robustness tests   
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12)
FE R&D Filter LOC D ORIGPAT ORIGPAT Controls Controls Controls NBER PUB/PAT PUB/PAT ACADPUB
LOG TOBIN'S Q WITHIN NLLS NLLS NLLS NLLS NLLS NLLS NLLS NLLS NLLS NLLS NLLS
Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE)
R&D/A 0.026*** 0.078*** 0.046*** 0.056*** 0.051*** 0.051*** 0.058*** 0.062*** 0.059*** 0.062*** 0.056*** 0.050***
(0.009) (0.014) (0.014) (0.015) (0.015) (0.015) (0.015) (0.015) (0.017) (0.017) (0.018) (0.015)
PAT/R&D 0.073*** 0.074*** 0.076*** 0.084*** 0.069*** 0.074*** 0.083*** 0.064*** 0.075** 0.057** 0.075** 0.071***
(0.019) (0.026) (0.025) (0.025) (0.026) (0.028) (0.026) (0.025) (0.030) (0.028) (0.030) (0.026)
PUB/R&D 0.058** 0.044 0.077* 0.102*** 0.064 0.072* 0.036 0.042 0.113*** 0.060
(0.027) (0.034) (0.040) (0.039) (0.039) (0.040) (0.039) (0.039) (0.043) (0.039)
PUB/PAT 0.269** 0.176
(0.111) (0.120)
FWDCIT/PAT 0.001 0.005*** 0.005** 0.005*** 0.006*** 0.007*** 0.006*** 0.006** 0.005***
(0.001) (0.002) (0.002) (0.002) (0.002) (0.002) (0.002) (0.003) (0.002)
SCIPAT/PAT -0.039 0.016 0.037 0.036 0.041 0.054 0.050 0.055 0.043
(0.027) (0.034) (0.037) (0.039) (0.040) (0.040) (0.039) (0.042) (0.038)
TOPPUB/PUB 0.033 0.116*** 0.135*** 0.139*** 0.155*** 0.173*** 0.155*** 0.215*** 0.111**
(0.027) (0.037) (0.041) (0.041) (0.044) (0.043) (0.042) (0.049) (0.046)
ORIGPAT/PAT 0.097*** 0.038
(0.032) (0.034)
ACADPUB/PUB 0.052
(0.039)
Firm-Year observations 9,920 11,420 9,920 9,920 9,920 9,154 9,920 9,920 7,392 7,407 7,407 9,920
Firm-IDs (cluster) 1,739 1998 1739 1.739 1.739 1593 1,739 1,739 1.575 1.312 1.312 1.739
R2 0.089 0.158 0.154 0.132 0.141 0.152 0.112 0.120 0.140 0.140 0.156 0.142
Standard errors (clustered by firm) reported in parentheses; *** p<0.01, ** p<0.05, * p<0.1. Models contain year and SIC-4 digit industry dummies.
Column (1): FE-"Within" estimator. (2): Filter that excludes R&D/Sales > 1 is deleted. (3): Location dummies (US State level) are added. (4) and (5): Patent originality measure 
(ORIGPAT/PAT) is introduced. The threshold for considering a patent as “original” has been set at the mean originality value of all patents filed by the sample firms. (6): Sales and Sales 
growth are included as control variables (see Belenzon 2011). The sample size is reduced since Sales growth requires observation of t-1. (7) contains sector-level patent and publication 
intensities (computed at NACE-3 level) as additional control variables and "metasector" industry controls. (8) contains a control variable that captures the share of firm's profits on 
industry profits (at SIC-3 digit level). (9): Patentcounts from the combined Compustat-NBER dataset is used instead of the variable obtained by our own matching. Sample limited to the 
period 1996-2002 since the NBER patent counts are increasingly incomplete for more recent years. (10) and (11): Alternative consideration of publications as ratio of publication stocks 
to patent stocks, for subsample of patenting firms. (12): Share co-authored publication stock with academic institutions is introduced.
